WallStreetZenWallStreetZen

NASDAQ: ADVM
Adverum Biotechnologies Inc Stock

$1.97-0.01 (-0.51%)
Updated Mar 1, 2024
ADVM Price
$1.97
Fair Value Price
-$0.39
Market Cap
$199.02M
52 Week Low
$0.68
52 Week High
$2.97
P/E
-1.56x
P/B
1.94x
P/S
42.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.60M
Earnings
-$126.19M
Gross Margin
100%
Operating Margin
-3,503.14%
Profit Margin
-3,505.2%
Debt to Equity
0.92
Operating Cash Flow
-$88M
Beta
1.14
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ADVM Overview

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ADVM ($1.97) is overvalued by 609.56% relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ADVM ($1.97) is not significantly undervalued (609.56%) relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADVM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADVM due diligence checks available for Premium users.

Be the first to know about important ADVM news, forecast changes, insider trades & much more!

ADVM News

Valuation

ADVM fair value

Fair Value of ADVM stock based on Discounted Cash Flow (DCF)
Price
$1.97
Fair Value
-$0.39
Undervalued by
609.56%
ADVM ($1.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADVM ($1.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADVM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ADVM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.56x
Industry
15.19x
Market
36.17x

ADVM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
6.18x
ADVM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ADVM's financial health

Profit margin

Revenue
$0.0
Net Income
-$32.9M
Profit Margin
0%
ADVM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADVM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$196.8M
Liabilities
$94.1M
Debt to equity
0.92
ADVM's short-term assets ($124.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADVM's short-term assets ($124.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADVM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.9M
Investing
$18.2M
Financing
-$105.0k
ADVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ADVM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ADVM$199.02M-0.51%-1.56x1.94x
GRPH$197.42M0.00%-1.55x1.08x
SLDB$197.13M+4.05%-2.16x1.37x
CRMD$201.16M+3.67%-4.27x2.42x
SGMO$196.86M-4.31%-0.77x1.46x

Adverum Biotechnologies Stock FAQ

What is Adverum Biotechnologies's quote symbol?

(NASDAQ: ADVM) Adverum Biotechnologies trades on the NASDAQ under the ticker symbol ADVM. Adverum Biotechnologies stock quotes can also be displayed as NASDAQ: ADVM.

If you're new to stock investing, here's how to buy Adverum Biotechnologies stock.

What is the 52 week high and low for Adverum Biotechnologies (NASDAQ: ADVM)?

(NASDAQ: ADVM) Adverum Biotechnologies's 52-week high was $2.97, and its 52-week low was $0.68. It is currently -33.67% from its 52-week high and 189.28% from its 52-week low.

How much is Adverum Biotechnologies stock worth today?

(NASDAQ: ADVM) Adverum Biotechnologies currently has 101,027,174 outstanding shares. With Adverum Biotechnologies stock trading at $1.97 per share, the total value of Adverum Biotechnologies stock (market capitalization) is $199.02M.

Adverum Biotechnologies stock was originally listed at a price of $27.99 in Jul 31, 2014. If you had invested in Adverum Biotechnologies stock at $27.99, your return over the last 9 years would have been -92.96%, for an annualized return of -25.54% (not including any dividends or dividend reinvestments).

How much is Adverum Biotechnologies's stock price per share?

(NASDAQ: ADVM) Adverum Biotechnologies stock price per share is $1.97 today (as of Mar 1, 2024).

What is Adverum Biotechnologies's Market Cap?

(NASDAQ: ADVM) Adverum Biotechnologies's market cap is $199.02M, as of Mar 3, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adverum Biotechnologies's market cap is calculated by multiplying ADVM's current stock price of $1.97 by ADVM's total outstanding shares of 101,027,174.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.